Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-HER-2 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Systemic
01
Overview
anti-HER-2 siRNA is a modified hybrid (DNA-RNA) small interfering RNA (siRNA) molecule developed as a potential anticancer therapeutic. It functions by specifically targeting and silencing the Human epidermal growth factor receptor 2 (HER2) gene, thereby inhibiting its transcription and reducing the expression of the HER2 protein. This gene silencing effect aims to sensitize tumor cells to chemotherapeutics and inhibit tumor growth. The drug is delivered via a nanosized immunoliposome-based complex (scL-HoKC) designed for systemic administration and preferential targeting of tumor cells, addressing challenges associated with siRNA delivery such as low transfection efficiency and poor tissue penetration.
- Other names
- anti-HER2 siRNA nanoparticleanti-HER-2 siRNA nanoparticleanti-HER 2 siRNA nanoparticlescL-anti-HER2 siRNAscL-anti-HER-2 siRNAscL-anti-HER 2 siRNAnanoimmunoliposome anti-HER-2 siRNA complex
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on anti-HER-2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-HER-2 siRNA.